The Hub for Disease-Specific Clinical Information
Editor:
Ursula A. Matulonis, MD
Advertisement
Advertisement

Recent News

FOXD3: Cellular Target Biomarker for Ovarian Cancer?
Ovarian Cancer’s Genetic Relationship to Other Cancers
Epithelial Ovarian Cancer: Clinical Relevance of Deregulation of Long Noncoding RNAs
Bioengineered Scaffolds: Another Step Toward Fertility Restoration?
Are Urine Biomarkers Ready for Prime Time in Detecting Early Ovarian Cancer?
Can Gene Fusions Alter Transcriptional Regulation in High-Grade Ovarian Cancer?
HOPA 2019: Intraperitoneal vs. Dose-Dense Chemotherapy in Stage III Ovarian Cancer
AACR 2019: Can Use of Oral Contraceptives Protect Against Aggressive Ovarian Cancer?
Rucaparib in Ovarian Cancer: Reversion Mutations in Predicting Treatment Resistance
SGO 2019: Dendritic Cell Vaccine Plus Chemotherapy in Ovarian Cancer
SGO 2019: Niraparib Maintenance and Quality of Life in Recurrent Ovarian Cancer
SGO 2019: Does Age Affect Efficacy of Rucaparib in Ovarian Cancer?
Role of Lymphadenectomy in Treating Ovarian Cancer
2019 ASCO-SITC Symposium: IL-12 Plasmid Plus Neoadjuvant Chemotherapy in Ovarian Cancer
Novel Antibody-Drug Conjugates in Ovarian Cancer
Targeting Chemotherapy-Resistant Ovarian Cancer
Enhancing Sensitivity to Oxaliplatin in Mucinous Ovarian Cancer
Toxicities Associated With PARP Inhibitors for Ovarian Cancer
Nonepithelial Ovarian Cancers: Surgical Procedures for Fertility Preservation
Genetic Similarities Identified in Primary and Metastatic Ovarian Tumors
Potential Assays for Pinpointing Ovarian, Endometrial Cancers
Do Patients With Low-Grade Serous Ovarian Carcinoma Benefit From Targeted Sequencing?
‘Sticky Webs of DNA’ in Pathogenesis of Ovarian Cancer
FDA Approves Olaparib for First-Line Maintenance of BRCA-Mutated, Advanced Ovarian Cancer
Novel Vascular Technique Being Studied in Advanced Ovarian Cancer
Shedding Light on Resistance to PARP Inhibitors in Patients With Ovarian Cancer
NICE Rejects Olaparib Tablets in Ovarian Cancer Maintenance Therapy
Durvalumab Plus Olaparib in BRCA-Mutant Ovarian Cancer
Apatinib After Second-Line Chemotherapy Failure in Advanced Ovarian Cancer
Copyright © 2019 National Comprehensive Cancer Network, All Rights Reserved
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.